Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842633 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
NCT01842633 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 365 participants.
The verdict
NCT01842633, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
Study Summary
The purpose of this multi-center study is to assess the efficacy of headache relief of new paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type headache (ETTH).
Interventions
- OTHER Placebo
- DRUG Ibuprofen
- DRUG Paracetamol and Caffeine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2015-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01842633
The ClinicalTrials.gov registry entry for NCT01842633 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01842633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01842633 about?
NCT01842633 is a clinical study titled "Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache". The purpose of this multi-center study is to assess the efficacy of headache relief of new paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type headache (ETTH).
What is the current status of trial NCT01842633?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2013-04-01. Estimated completion is 2015-03-31.
What interventions are being tested in trial NCT01842633?
The interventions under investigation include: Placebo (OTHER), Ibuprofen (DRUG), Paracetamol and Caffeine (DRUG).
Who is sponsoring clinical trial NCT01842633?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.